Zobrazeno 71 - 80
of 1 482
pro vyhledávání: ''
Autor:
Jianjiang Wang, Xu Du, Lijiang Yu, Changchun Sun, Xi Yang, Yong Ji, Yufeng Huang, Sun Di, Chenggong Zhang, Wu Yang, Yiqian Liu, Chunmu Tao, Zhao Wang
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 12, Iss 4, Pp 1-12 (2021)
Cell Death and Disease, Vol 12, Iss 4, Pp 1-12 (2021)
As a result of mutations in the upstream components of the Wnt/β-catenin signaling pathway, this cascade is abnormally activated in colon cancer. Hence, identifying the activation mechanism of this pathway is an urgent need for the treatment of colo
Autor:
Yang Zheng, An Song, Chundi Wang, Wei Zhang, Dong Liang, Xu Ding, Gang Li, Hongchuang Zhang, Yifei Du, Junbo Zhou, Heming Wu, Yunong Wu, Xiaomeng Song
Publikováno v:
Cell Death and Disease, Vol 11, Iss 8, Pp 1-15 (2020)
Cell Death & Disease
Cell Death & Disease
Our group previously identified that the NOTCH1 Abruptex domain contains the most mutations in Chinese OSCC patients, including a hotspot mutation (C1133Y). FBXW7 is an E3 ubiquitin ligase that regulates a network of proteins, including NOTCH1, via d
Autor:
Daphne Wang, Taha Merghoub, Jarushka Naidoo, Jinny Ha, David R. Jones, Marianna Zahurak, Joseph C. Murray, Ben Levy, Kellie N. Smith, Stephen R. Broderick, Drew M. Pardoll, Suzanne L. Topalian, Jamie E. Chaft, Richard J. Battafarano, Valsamo Anagnostou, Errol L. Bush, Janis M. Taube, Victor E. Velculescu, Mara Lanis, Peter B. Illei, Matthew D. Hellmann, Malcolm V. Brock, Gary L. Rosner, Hok Yee Chan, James R. White, Franco Verde, Joshua E. Reuss, Caroline G. McCarthy, Patrick M. Forde, Tricia R. Cottrell, Stephen C. Yang, Julie R. Brahmer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundWe conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with an encouraging rate of pathologic response. Building on these results, an
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 8, Pp 1-13 (2020)
Cell Death and Disease, Vol 11, Iss 8, Pp 1-13 (2020)
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. LncRNA small nucleolar RNA host gene 14 (SNHG14) functions as an oncogene in a variety of cancers. However, the role of SNHG14 in HCC remains elusive. The aim of this study is
Autor:
Lili Zheng, Tingting Liu, Yuanyuan Fang, Guijun Qin, Lixia Zhang, Kelei Guan, Lijun Xu, Juntao Pan, Tingting Wang, Xiaolong Chen, Zhifang Wang, Wenhua Xue
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 8, Pp 1-16 (2020)
Cell Death and Disease, Vol 11, Iss 8, Pp 1-16 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and the therapeutic outcomes remain undesirable. Increasing evidence shows that aryl hydrocarbon receptor nuclear translocator like 2 (ARNTL2) plays crucial roles in t
Publikováno v:
Cancer immunology, immunotherapy : CII. 70(8)
Tumor mutation burden (TMB) predicts response to immunotherapy in non-small cell lung cancer (NSCLC). The current TMB evaluation is expensive and not satisfactory. Here, novel tumor mutation score (TMS) was defined as the number of genes with mutatio
Autor:
Thomas F. Gajewski, Kyle R. Cron
Publikováno v:
The Journal of Experimental Medicine
Type 1 conventional dendritic cells are progressively and systemically dysregulated during pancreatic carcinogenesis, subject to semimaturation and IL-6–driven apoptosis. Yet, CD40 agonist synergizes with Flt3L to rescue cDC1 abundance and maturati
Autor:
Haruhiko Nakamura, Hisashi Saji, Ayako Yachie, Takeshi Hase, Toshihide Nishimura, Saeko Naruki, Harubumi Kato, Masayuki Takagi, Kiyonaga Fujii, Hirotaka Koizumi, Yukiko Matsuoka, Naoki Furuya
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
It is unclear how epidermal growth factor receptor EGFR major driver mutations (L858R or Ex19del) affect downstream molecular networks and pathways. This study aimed to provide information on the influences of these mutations. The study assessed 36 p
Autor:
Ming-Chih Hou, Ming-Huang Chen, Yee Chao, Pei-Chang Lee, I-Cheng Lee, Keng-Hsin Lan, Yi Hsiang Huang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundImmunotherapy with immune checkpoint inhibitor (ICI) is a promising treatment for unresectable hepatocellular carcinoma (HCC). However, whether ICIs would have the risk of hepatitis B virus (HBV) reactivation and the necessary of nucleos(t)
Autor:
Marco L. Davila, Paulo C. Rodriguez, Claudio Anasetti, Erin Dean, Kristen Spitler, Biwei Cao, Hua Zhao, Xuefeng Wang, Michael D. Jain, Reginald Atkins, Kayla Reid, Taiga Nishihori, Bijal D. Shah, Aleksandr Lazaryan, Frederick L. Locke, Meghan Menges, Mohammed Hussaini, Rawan Faramand, Jose R. Conejo-Garcia, Christina A Bachmeier, Julio C. Chavez, Ricardo J. Gonzalez, John E. Mullinax
Publikováno v:
Blood
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune dysregulation, present before CAR T-cell therapy, was associated with t